Hopp til innhold
NHI.no
Annonse

Pneumocystose: Behandling

Innhold i artikkelen

Målet med behandlingen er å fjerne mikroorganismen, dvs. kurere infeksjonen, og sikre at pasienten overlever. Pasienter med milde symptomer på pneumocystis lungebetennelse kan behandles utenfor sykehus med tabletter og hyppige kontroller. Ved alvorligere symptomer må pasienten innlegges og behandles på sykehus. Behandlingen er antibiotika, men det er ikke alltid at virkningen er tilfredsstillende. Bivirkninger forekommer også.

Annonse

Forebyggende behandling startes straks man er oppmerksom på at en pasient er smittet med hiv, og vil normalt forhindre hiv-smittede i å utvikle denne betennelsen. Pasienter som er immunsvekket av annen årsak enn hiv, vurderes også for forebyggende behandling.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Pneumocystose . Referanselisten for dette dokumentet vises nedenfor

  1. Smittevernveilederen. Pneumocystose - veileder for helsepersonell. Folkehelseinstituttet, sist oppdatert 07.07.2019. www.fhi.no
  2. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350: 2487-98. PubMed
  3. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among hiv-infected persons -- 2002: recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137: 435-478. Annals of Internal Medicine
  4. Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;(4):CD006150. Cochrane (DOI)
  5. Kim JH, Psevdos G Jr, Gonzalez E, et al. All-cause mortality in hospitalized hiv-infected patients at an acute tertiary care hospital with a comprehensive outpatient hiv care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection 2013;41:545-551 PubMed
  6. Manoloff ES, Francioli P, Taffe P, Van Melle G, Bille J, Hauser PM. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003; 9: 132-4. PubMed
  7. Wakefield AE, Lindley AR, Ambrose HE, Denis CM, Miller RF. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 2003; 187: 901-8. PubMed
  8. Morris A, Konstantinidis I. Pneumocystis jirovecii pneumonia. BestPractice, last updated 26 Jan 2021.
  9. Ebner L, Walti LN, Rauch A, Furrer H, Cusini A, Meyer AM, et al. Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients. PLoS One. 2016; 11: e0164320.
  10. Chou CW, Chao HS, Lin FC, Tsai HC, Yuan WH, Chang SC. Clinical Usefulness of HRCT in Assessing the Severity of Pneumocystis jirovecii Pneumonia: A Cross-sectional Study. Medicine (Baltimore). 2015; 94: e768. PubMed
  11. Limper AH, Knox KS, Sarosi GA, et al. An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011;183:96-128. PubMed
  12. Kaplan JE, Benson C, Holmes KH, , et al. Guidelines for prevention and treatment of opportunistic infections in hiv-infected adults and adolescents, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the hiv Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009 Apr 10;58(RR-4):1-207.
  13. Randall Curtis J, Yarnold PR, Schwartz DN, Weinstein RA, Bennett CL. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2000; 162: 393-398. PubMed
  14. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-hiv Pneumocystis carinii pneumonia. Chest 1998; 113: 1215-1224. PubMed
Annonse
Annonse